H
Hidetomo Nakamoto
Researcher at Saitama Medical University
Publications - 204
Citations - 4626
Hidetomo Nakamoto is an academic researcher from Saitama Medical University. The author has contributed to research in topics: Peritoneal dialysis & Dialysis. The author has an hindex of 35, co-authored 187 publications receiving 4033 citations. Previous affiliations of Hidetomo Nakamoto include Yahoo! & Keio University.
Papers
More filters
Journal ArticleDOI
Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study
Hiroo Kumagai,Toshiya Ebata,Kenji Takamori,Taro Muramatsu,Hidetomo Nakamoto,Hiromichi Suzuki +5 more
TL;DR: This Phase III, randomized, double-blind, placebo-controlled, parallel-group, prospective study based on VAS evaluations clearly showed that orally taken nalfurafine hydrochloride effectively reduced itches that were otherwise refractory to currently available treatments in maintenance haemodialysis patients, with few significant ADRs.
Journal ArticleDOI
Overview of Regular Dialysis Treatment in Japan (as of 31 December 2011)
Shigeru Nakai,Yuzo Watanabe,Ikuto Masakane,Atsushi Wada,Tetsuo Shoji,Takeshi Hasegawa,Hidetomo Nakamoto,Kunihiro Yamagata,Junichiro James Kazama,Naohiko Fujii,Noritomo Itami,Toshio Shinoda,Takashi Shigematsu,Seiji Marubayashi,Osamu Morita,Seiji Hashimoto,Kazuyuki Suzuki,Naoki Kimata,Norio Hanafusa,Kenji Wakai,Takayuki Hamano,Satoshi Ogata,Kenji Tsuchida,Masatomo Taniguchi,Hiroshi Nishi,Kunitoshi Iseki,Yoshiharu Tsubakihara +26 more
TL;DR: A nationwide statistical survey of 4255 dialysis facilities was conducted at the end of 2011 and the results included questions related to the Great East Japan Earthquake, which occurred on 11 March 2011.
Journal ArticleDOI
Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.
TL;DR: In patients with hypertension starting CAPD therapy, valsartan slows the decline in residual renal function and contributes to maintenance of weekly creatinine clearance and Kt/V (fraction per dialysis), which are the major factors contributing to the mortality and morbidity of CAPD patients.
Journal ArticleDOI
Overview of regular dialysis treatment in Japan (as of 31 December 2008).
Shigeru Nakai,Kazuyuki Suzuki,Ikuto Masakane,Atsushi Wada,Noritomo Itami,Satoshi Ogata,Naoki Kimata,Takashi Shigematsu,Toshio Shinoda,Tetsuo Syouji,Masatomo Taniguchi,Kenji Tsuchida,Hidetomo Nakamoto,Shinichi Nishi,Hiroshi Nishi,Seiji Hashimoto,Takeshi Hasegawa,Norio Hanafusa,Takayuki Hamano,Naohiko Fujii,Seiji Marubayashi,Osamu Morita,Kunihiro Yamagata,Kenji Wakai,Yuzo Watanabe,Kunitoshi Iseki,Yoshiharu Tsubakihara +26 more
TL;DR: The risk of becoming HCV‐positive was high in patients with low serum creatinine, serum albumin, and serum total cholesterol levels, and/or a low body mass index before beginning dialysis, and the percentage is particularly high in Patients with a period of dialysis of 20 years or longer.
Journal ArticleDOI
Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures
Yoshindo Kawaguchi,Akira Saito,Hideki Kawanishi,Masaaki Nakayama,Masanobu Miyazaki,Hidetomo Nakamoto,Anders Tranaeus +6 more
TL;DR: This comprehensive update on the management of encapsulating peritoneal sclerosis incorporates insights gained from recently published findings and the accumulated experience of the authors.